salubris pharmaceuticals (sz code:002294）today announces that china national medical products administration (nmpa) has approved the phase i clinical trial application of sal0114 tablets for the treatment of patients with ad agitation.
nmpa approved previously the phase i clinical trial application of sal0114 tablets for the treatment of patients with clinical depression.
at present, there is no drug approved for the treatment of patients with ad agitation worldwide. the successful launch of sal0114 tablets will further meet the huge unmet clinical needs and provide new medication options for patients.
in future, with the core value of "patient-centered” in mind, salubris pharmaceuticals will continue to make efforts in the drive of pharmaceutical r & d and innovation, focusing on unmet clinical needs to provide excellent pharmaceutical products for human health.
for alzheimer’s disease (ad)
alzheimer's disease (ad) as a complex neurodegenerative disease, is the most common type of dementia①. due to its complex and inconclusive pathogenesis , lack of proper understanding of the disease is the underlying cause of the absence of drugs that can reverse the course of the disease ②. the prevalence of alzheimer's disease in china among aged 65 years and older is 4.2% in the northern region and 2.8% in the southern region③. among them, the prevalence increases year by year with age. alzheimer's disease is typically characterized clinically by a progressive decline in cognitive function and executive performance, and a range of neuropsychiatric symptoms (nps) that accompany the entire course of the disease. among all the npss, the most common symptoms are indifference and depression; however, agitated behavior is one of the most harmful behaviors that afflict patients and their families①.
references:
①advances in the treatment of agitation associated with alzheimer's disease
author affiliation: department of neurology, the second affiliated hospital of harbin medical university, harbin, heilongjiang
corresponding author: zhang xuemei
②research progress in targets of alzheimer's disease and related drugsauthor: wang jiafan, chen song, gao xiangdong
③ practical internal medicine (15th edition)